参考文献 [1] Ameya S. K, Sandra A, David M. B, et al.(2022). Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization, Aging cell, 21(4), e13596. https://doi.org/10.1111/acel.13596 [2] Maria R R, Irene D M, Rita P, et a...
[1]SGLT2Inhibitor Diabetes Drugs May Cause Ketoacidosis: FDA. Medscape. May 15, 2015. [2]Vallon V, GerasimovaM, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth andalbuminuria in proportion to hyperglycemia and prevents glomerular...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a relatively new class of antidiabetic drugs that in addition to emerging as an effective antihyperglycemic treatment have been shown to improve, in several trials, both renal and cardiovascular outcomes. In consideration of the renal site of ...
1. Madaan, Tushar,Akhtar, Mohd., Najmi, Abul Kalam, Sodium glucose CoTransporter 2 (SGLT2)inhibitors: Current status and future perspective, (2016), doi:10.1016/j.ejps.2016.08.025 2. A new class ofdrugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.Journal of Cardiology...
Invokanaand similar diabetes drugs double the risk of ketoacidosis compared to DPP-4inhibitor diabetes drugs 研究人员MichaelFralick博士也强调,尽管酮症酸中毒的风险增加一倍,听起来很可怕,但实际风险很小,预计风险是每1000名患者中会有5-8例酮症酸中毒。
Dec 14, 2022, from https://medicalxpress.com/news/2022-12-class-diabetes-drugs-dementia-older.html 免责声明:药明康德内容团队专注介绍全 球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代表药明康德立场,亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导,请前往...
"Cardiovascular disease is the main cause of death in older adults in the U.S.," said Camila Manrique-Acevedo, MD, associate professor of medicine. "Weight loss, physical activity, antihypertensive therapy and lipid-low...
[1].FDA.https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. [2].EMA.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/03/WC500203804.pdf. [3].Zinman B et al. N Engl J Med 2015;373:2117-28. ...
9. Avgerinos I, Manolopoulos A, Michailidis T, Kitsios K, Liakos A, Karagiannis T, et al. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23(3):822-...
2. A new class ofdrugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.Journal of Cardiology 71 (2018) 471–476.doi.org/10.1016/j.jjcc.2017.12.004 3. Synthetic strategyand SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review,European Journal of Medicinal Che...